Safety of an extension of use of pasteurised Akkermansia muciniphila as a novel food pursuant to Regulation (EU) 2015/2283

Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the safety of an extension of use of pasteurised Akkermansia muciniphila as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The extension pe...

ver descrição completa

Detalhes bibliográficos
Autores: EFSA NDA Panel (EFSA Panel on Nutrition, Novel Foods and Food Allergens), Turck, D., Bohn, T., Cámara, M, Castenmiller, J., De Henauw, S., Jos Gallego, Ángeles Mencía, Maciuk, A., Mangelsdorf, I., Hirsch-Ernst, K. I.
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2025
País:España
Recursos:Universidad de Sevilla (US)
Repositório:idUS. Depósito de Investigación de la Universidad de Sevilla
OAI Identifier:oai:idus.us.es:11441/182471
Acesso em linha:https://hdl.handle.net/11441/182471
https://doi.org/10.2903/j.efsa.2025.9632
Access Level:Acceso aberto
Palavra-chave:Akkermansia muciniphila
Extension of use
Gut microbiota
Microorganism
Novel food
Safety
Descrição
Resumo:Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the safety of an extension of use of pasteurised Akkermansia muciniphila as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The extension pertains to the use of the NF in food supplements and Foods for Special Medical Purposes (FSMPs) for adolescents from 12 to < 18 years of age and to pregnant and lactating women. The maximum proposed daily doses of the NF correspond to about 4.8 × 108 cells/kg bodyweight per day, which was the safe dose as established for the NF by the Panel in 2021. The newly identified toxicological and human studies with A. muciniphila from various strains, including the strain to which the NF belongs, do not raise safety concerns in view of the extension of use of the NF for adolescents from 12 years of age. However, no evidence was provided for the safety of the NF in pregnant and lactating women. The Panel concludes that the NF, pasteurised A. muciniphila, is safe at doses up to 2.1 × 1010 cells/day for adolescents from 12 to < 14 years and 3.0 × 1010 cells/day for adolescents from 14 years until < 18 years. The safety of the NF in pregnant and lactating women has not been established.